Merck to acquire Acceleron Pharma for $11.5 billion

Merck (known as MSD outside US and Canada) announced a definitive agreement to acquire Acceleron Pharma Inc. for $180 per share in cash, totaling approximately $11.5 billion equity value. Acceleron focuses on TGF-beta superfamily therapies, including sotatercept for pulmonary arterial hypertension and REBLOZYL for anemia.

“Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion.”merck.com

• 1 source
• merck.comMerck to Acquire Acceleron Pharma Inc.Merck, Co., Inc., Rahway, NJ, USASep 30, 2021

Summarized from public sources; check the original articles before acting on it.